Christine A Sorkness1, Jeremy J Wildfire2, Agustin Calatroni2, Herman E Mitchell2, William W Busse3, George T O'Connor4, Jacqueline A Pongracic5, Kristie Ross6, Michelle A Gill7, Meyer Kattan8, Wayne J Morgan9, Stephen J Teach10, Peter J Gergen11, Andrew H Liu12, Stanley J Szefler12. 1. University of Wisconsin School of Medicine and Public Health, Madison, Wis. Electronic address: sorkness@wisc.edu. 2. Rho Federal Systems Division, Inc, Chapel Hill, NC. 3. University of Wisconsin School of Medicine and Public Health, Madison, Wis. 4. Boston University School of Medicine, Boston, Mass. 5. Children's Memorial Hospital, Chicago, Ill. 6. Case Western Reserve University, Cleveland, Ohio. 7. University of Texas Southwestern Medical Center, Dallas, Tex. 8. College of Physicians and Surgeons, Columbia University, New York, NY. 9. University of Arizona College of Medicine, Tucson, Ariz. 10. Children's National Medical Center, Washington, DC. 11. National Institute of Allergy and Infectious Diseases, Bethesda, Md. 12. National Jewish Health and University of Colorado School of Medicine, Denver, Colo.
Abstract
BACKGROUND: Treatment regimens for omalizumab are guided by a dosing table that is based on total serum IgE and body weight. Limited data exist about onset and offset of omalizumabefficacy in children and adolescents or subgroups that most benefit from treatment. OBJECTIVES: Post hoc analyses were conducted to (1) examine patient characteristics of those eligible and ineligible for omalizumab, (2) describe onset of effect after initiation of omalizumab and offset of treatment effect after stopping therapy, and (3) determine whether the efficacy differs by age, asthma severity, dosing regimen, and prespecified biomarkers. METHODS:Inner-city children and adolescents with persistent allergic asthma were enrolled in the Inner-City Anti-IgE Therapy for Asthma trial that compared omalizumab with placebo added to guidelines-based therapy for 60 weeks. RESULTS:Two hundred ninety-three of 889 participants (33%) clinically suitable for omalizumab were ineligible for dosing according to a modified dosing table specifying IgE level and body weight criteria. Baseline symptoms were comparable among those eligible and ineligible to receive omalizumab, but other characteristics (rate of health care utilization and skin test results) differed. The time of onset of omalizumab effect was <30 days and time of offset was between 30 and 120 days. No difference in efficacy was noted by age or asthma severity, but high exhaled nitric oxide, blood eosinophils, and body mass index predicted efficacy. CONCLUSIONS: A significant portion of children and adolescents particularly suited for omalizumab because of asthma severity status may be ineligible due to IgE >1300 IU/mL. Omalizumab reduced asthma symptoms and exacerbations rapidly; features associated with efficacy can be identified to guide patient selection.
RCT Entities:
BACKGROUND: Treatment regimens for omalizumab are guided by a dosing table that is based on total serum IgE and body weight. Limited data exist about onset and offset of omalizumab efficacy in children and adolescents or subgroups that most benefit from treatment. OBJECTIVES: Post hoc analyses were conducted to (1) examine patient characteristics of those eligible and ineligible for omalizumab, (2) describe onset of effect after initiation of omalizumab and offset of treatment effect after stopping therapy, and (3) determine whether the efficacy differs by age, asthma severity, dosing regimen, and prespecified biomarkers. METHODS: Inner-city children and adolescents with persistent allergic asthma were enrolled in the Inner-City Anti-IgE Therapy for Asthma trial that compared omalizumab with placebo added to guidelines-based therapy for 60 weeks. RESULTS: Two hundred ninety-three of 889 participants (33%) clinically suitable for omalizumab were ineligible for dosing according to a modified dosing table specifying IgE level and body weight criteria. Baseline symptoms were comparable among those eligible and ineligible to receive omalizumab, but other characteristics (rate of health care utilization and skin test results) differed. The time of onset of omalizumab effect was <30 days and time of offset was between 30 and 120 days. No difference in efficacy was noted by age or asthma severity, but high exhaled nitric oxide, blood eosinophils, and body mass index predicted efficacy. CONCLUSIONS: A significant portion of children and adolescents particularly suited for omalizumab because of asthma severity status may be ineligible due to IgE >1300 IU/mL. Omalizumab reduced asthma symptoms and exacerbations rapidly; features associated with efficacy can be identified to guide patient selection.
Authors: D L Rosenstreich; P Eggleston; M Kattan; D Baker; R G Slavin; P Gergen; H Mitchell; K McNiff-Mortimer; H Lynn; D Ownby; F Malveaux Journal: N Engl J Med Date: 1997-05-08 Impact factor: 91.245
Authors: J V Fahy; H E Fleming; H H Wong; J T Liu; J Q Su; J Reimann; R B Fick; H A Boushey Journal: Am J Respir Crit Care Med Date: 1997-06 Impact factor: 21.405
Authors: William W Busse; Wayne J Morgan; Peter J Gergen; Herman E Mitchell; James E Gern; Andrew H Liu; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Jacqueline A Pongracic; James F Chmiel; Suzanne F Steinbach; Agustin Calatroni; Alkis Togias; Katherine M Thompson; Stanley J Szefler; Christine A Sorkness Journal: N Engl J Med Date: 2011-03-17 Impact factor: 91.245
Authors: M Solèr; J Matz; R Townley; R Buhl; J O'Brien; H Fox; J Thirlwell; N Gupta; G Della Cioppa Journal: Eur Respir J Date: 2001-08 Impact factor: 16.671
Authors: E C Matsui; H A Sampson; H T Bahnson; R S Gruchalla; J A Pongracic; S J Teach; P J Gergen; G R Bloomberg; J F Chmiel; A H Liu; M Kattan; C A Sorkness; S F Steinbach; R E Story; C M Visness Journal: Allergy Date: 2010-11 Impact factor: 13.146
Authors: M Humbert; R Beasley; J Ayres; R Slavin; J Hébert; J Bousquet; K-M Beeh; S Ramos; G W Canonica; S Hedgecock; H Fox; M Blogg; K Surrey Journal: Allergy Date: 2005-03 Impact factor: 13.146
Authors: Rebecca S Gruchalla; Jacqueline Pongracic; Marshall Plaut; Richard Evans; Cynthia M Visness; Michelle Walter; Ellen F Crain; Meyer Kattan; Wayne J Morgan; Suzanne Steinbach; James Stout; George Malindzak; Ernestine Smartt; Herman Mitchell Journal: J Allergy Clin Immunol Date: 2005-03 Impact factor: 10.793
Authors: Wayne J Morgan; Ellen F Crain; Rebecca S Gruchalla; George T O'Connor; Meyer Kattan; Richard Evans; James Stout; George Malindzak; Ernestine Smartt; Marshall Plaut; Michelle Walter; Benjamin Vaughn; Herman Mitchell Journal: N Engl J Med Date: 2004-09-09 Impact factor: 91.245
Authors: Stephen J Teach; Michelle A Gill; Alkis Togias; Christine A Sorkness; Samuel J Arbes; Agustin Calatroni; Jeremy J Wildfire; Peter J Gergen; Robyn T Cohen; Jacqueline A Pongracic; Carolyn M Kercsmar; Gurjit K Khurana Hershey; Rebecca S Gruchalla; Andrew H Liu; Edward M Zoratti; Meyer Kattan; Kristine A Grindle; James E Gern; William W Busse; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2015-10-27 Impact factor: 10.793
Authors: Sheel N Shah; Jocelyn R Grunwell; Ahmad F Mohammad; Susan T Stephenson; Gerald B Lee; Brian P Vickery; Anne M Fitzpatrick Journal: J Allergy Clin Immunol Pract Date: 2021-03-27
Authors: Alessandra Chiappori; Laura De Ferrari; Chiara Folli; Pierluigi Mauri; Anna Maria Riccio; Giorgio Walter Canonica Journal: Clin Mol Allergy Date: 2015-10-01
Authors: Matteo Ferrando; Diego Bagnasco; Gilda Varricchi; Stefano Bernardi; Alice Bragantini; Giovanni Passalacqua; Giorgio Walter Canonica Journal: Allergy Asthma Immunol Res Date: 2017-01 Impact factor: 5.764
Authors: William J Sheehan; Rebecca Z Krouse; Agustin Calatroni; Peter J Gergen; James E Gern; Michelle A Gill; Rebecca S Gruchalla; Gurjit K Khurana Hershey; Meyer Kattan; Carolyn M Kercsmar; Carin I Lamm; Frederic F Little; Melanie M Makhija; Daniel A Searing; Edward Zoratti; William W Busse; Stephen J Teach Journal: J Allergy Clin Immunol Pract Date: 2020-05-04